Cancer is one of the world’s most pressing health care challenges. On the whole, research progress from one year to the next is incremental, and true breakthroughs are exceptional. Nevertheless, every year brings new knowledge and insights that help direct further research and ultimately improve the outlook for patients with cancer. Clinical Cancer Advances 2017 highlights the most important clinical advances of the past year and previews where cancer science is headed. Advances highlighted
As of December 2016, there are now TWO patient advocates on the NCI Renal Task Force.
The US National Cancer Institute’s Renal Task Force is an advisory group that involves the renal oncology community to address the design and prioritization of NCI funded phase 2 and phase 3 clinical trials in renal cell cancer.
Deb Maskens joins the Task Force as a Patient Advocate from the IKCC (International Kidney
The KCSN Patient Champion Programmed works to build awareness of clinical trials and encourage patients to consider participation.
Results from a phase 2 study of sonepcizumab were published in the journal Cancer this week and showed encouraging overall survival and a favourable safety profile, although the study did not reach its primary endpoint of 2-month progression-free survival (PFS). However, despite the modest PFS (mean of 2.2 months), the encouraging overall survival warrant further investigation of sonepcizumab in combination with immunotherapies and vascular endothelial growth factor (VEGF) inhibitors. <a href="http://www.healio.com/hematology-oncology/genitourinary-cancer/news/in-the-journals/%7B8d65ed95-3a09-4f92-bd0e-1487c53a7d19%7D/sonepcizumab-shows-promise-for-metastatic-renal-cell-carcinoma
Results from the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for relapse. Read more